{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T04:05:59Z","timestamp":1726632359289},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.medcli.2024.04.007","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:57:10Z","timestamp":1718733430000},"page":"e69-e77","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Actualizaci\u00f3n de las recomendaciones para el diagn\u00f3stico y tratamiento de la amiloidosis por transtiretina variante (ATTRv)"],"prefix":"10.1016","volume":"163","author":[{"given":"Juan","family":"Gonz\u00e1lez-Moreno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Gal\u00e1n D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Gonzalez-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Concei\u00e7ao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2024.04.007_bib0160","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: Clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.medcli.2024.04.007_bib0165","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/13506129.2017.1292902","article-title":"Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: A global synthesis of 532 cases","volume":"24","author":"Cruz","year":"2017","journal-title":"Amyloid."},{"key":"10.1016\/j.medcli.2024.04.007_bib0170","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","article-title":"Amyloid nomenclature 2022: Update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"29","author":"Buxbaum","year":"2022","journal-title":"Amyloid."},{"key":"10.1016\/j.medcli.2024.04.007_bib0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"20","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.medcli.2024.04.007_bib0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid."},{"key":"10.1016\/j.medcli.2024.04.007_bib0185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jns.12451","article-title":"The neuropathy in hereditary transthyretin amyloidosis: A narrative review","volume":"26","author":"Tozza","year":"2021","journal-title":"J Peripher Nerv Syst."},{"key":"10.1016\/j.medcli.2024.04.007_bib0190","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","article-title":"Familial amyloid polyneuropathy","volume":"10","author":"Plant\u00e9-Bordeneuve","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medcli.2024.04.007_bib0195","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1055\/s-0039-1688977","article-title":"Small fiber neuropathy","volume":"39","author":"Zhou","year":"2019","journal-title":"Semin Neurol."},{"key":"10.1016\/j.medcli.2024.04.007_bib0200","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/brainsci10120989","article-title":"Contribution of skin biopsy in peripheral neuropathies","volume":"10","author":"Nolano","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.medcli.2024.04.007_bib0205","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.clinph.2020.01.022","article-title":"Quantitative sudomotor test helps differentiate transthyretin familial amyloid polyneuropathy from chronic inflammatory demyelinating polyneuropathy","volume":"131","author":"Fortanier","year":"2020","journal-title":"Clin Neurophysiol."},{"key":"10.1016\/j.medcli.2024.04.007_bib0210","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2337\/dc10-1303","article-title":"Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments","volume":"33","author":"Tesfaye","year":"2010","journal-title":"Diabetes Care."},{"key":"10.1016\/j.medcli.2024.04.007_bib0215","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.medcli.2024.04.007_bib0220","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.recesp.2019.12.017","article-title":"Perfil cl\u00ednico y evoluci\u00f3n de la amiloidosis cardiaca en un centro espa\u00f1ol de referencia","volume":"74","author":"L\u00f3pez-Sainz","year":"2021","journal-title":"Rev Espa\u00f1ola Cardiol."},{"key":"10.1016\/j.medcli.2024.04.007_bib0225","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to image cardiac amyloidosis: A practical approach","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging."},{"key":"10.1016\/j.medcli.2024.04.007_bib0230","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.medcli.2020.06.064","article-title":"Transthyretin amyloid cardiomyopathy","volume":"156","author":"Garcia-Pavia","year":"2021","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2024.04.007_bib0235","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.medcli.2024.04.007_bib0240","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/13506129.2015.1015678","article-title":"Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: A review of 513 cases","volume":"22","author":"Beir\u00e3o","year":"2015","journal-title":"Amyloid."},{"key":"10.1016\/j.medcli.2024.04.007_bib0245","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/13506129.2018.1564903","article-title":"Electrophysiological demyelinating features in hereditary ATTR amyloidosis","volume":"26","author":"Ohashi","year":"2019","journal-title":"Amyloid."},{"key":"10.1016\/j.medcli.2024.04.007_bib0250","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)","volume":"25","author":"Phull","year":"2018","journal-title":"Amyloid."},{"key":"10.1016\/j.medcli.2024.04.007_bib0255","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40265-019-01129-6","article-title":"Tafamidis: A review in transthyretin amyloidosis with polyneuropathy","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs."},{"key":"10.1016\/j.medcli.2024.04.007_bib0260","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid."},{"key":"10.1016\/j.medcli.2024.04.007_bib0265","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.medcli.2024.04.007_bib0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid."},{"key":"10.1016\/j.medcli.2024.04.007_bib0275","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/WCO.0000000000000852","article-title":"Hereditary transthyretin amyloidosis: Current treatment","volume":"33","author":"Adams","year":"2020","journal-title":"Curr Opin Neurol."},{"key":"10.1016\/j.medcli.2024.04.007_bib0280","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/ajt.17009","article-title":"Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation","volume":"22","author":"Schmidt","year":"2022","journal-title":"Am J Transplant."},{"key":"10.1016\/j.medcli.2024.04.007_bib0285","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2024.04.007_bib0290","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/13506129.2016.1272453","article-title":"Standard heart failure medication in cardiac transthyretin amyloidosis: Useful or harmful?","volume":"24","author":"Aus dem Siepen","year":"2017","journal-title":"Amyloid."},{"key":"10.1016\/j.medcli.2024.04.007_bib0295","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest."},{"key":"10.1016\/j.medcli.2024.04.007_bib0300","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","article-title":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","volume":"37","author":"Kristen","year":"2018","journal-title":"J Heart Lung Transplant."},{"key":"10.1016\/j.medcli.2024.04.007_bib0305","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","article-title":"ATTR amyloidosis: Current and emerging management strategies: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"Griffin","year":"2021","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.medcli.2024.04.007_bib0310","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324002690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324002690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T18:23:22Z","timestamp":1726597402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775324002690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0025775324002690"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2024.04.007","relation":{},"ISSN":["0025-7753"],"issn-type":[{"type":"print","value":"0025-7753"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualizaci\u00f3n de las recomendaciones para el diagn\u00f3stico y tratamiento de la amiloidosis por transtiretina variante (ATTRv)","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2024.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}